LGM Pharma Launches New Stand-Alone Analytical Services Offering for Drug Developers & Manufacturers

LGM Pharma, a long-time leader in API sourcing, completed a transformational acquisition last year of long-established CDMO NexGen Pharma. Among the many new capabilities LGM Pharma gained from the acquisition were first rate Analytical Services.

LGM Pharma is now making its highly experienced Analytical Services personnel and facilities available as a standalone service to pharma and biotech drug developers and manufacturers, as well as compounding pharmacies.

LGM Pharma’s Analytical Testing and Stability Services resources include:

  • A network of CGMP facilities in California, Colorado, and Texas
  • State-of-the-art chromatography and spectroscopy equipment
  • Over 60 QA, QC, and analytical staff members
  • Allowing LGM Pharma to deliver high quality, precise, client-specific, timely analytical and stability testing and reporting for drug substances, excipients, and drug products.

With its expanded CDMO service offerings, LGM Pharma Is offering clients a range of flexible contractual arrangements, including standard and preferred Vendor contracts, along with other individualized options.

Company representatives are available for virtual interviews during DCAT Week 2021.  I know you will be hearing more during DCAT week.  Let me know if you need any follow up information.